Opendata, web and dolomites

OmnImmune SIGNED

Manufacturing and testing of an allogeneic gamma delta T cell therapy for the treatment of cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OmnImmune project word cloud

Explore the words cloud of the OmnImmune project. It provides you a very rough idea of what is the project "OmnImmune" about.

units    lower    multifunctional    patient    population    administered    trial    disruptive    cells    gdt    variety    epidemic    treat    breakthrough    ready    profile    confirmed    therapies    first    vitro    instrument    stage    re    brings    cancer    patients    sme    scottish    frozen    treatments    status    trials    ease    considerable    years    cell    generation    multiple    immune    20    donors    healthy    predicted    data    valuable    quality    competitors    2024    radiation    administration    europe    accelerate    therapy    dose    time    demonstrated    experiencing    ageing    recipients    minimal    saving    manufactured    omnimmune    harvested    escalation    hospitalized    changing    24bn    expanded    surgery    truly    efficacy    oncology    disease    autologous    tcb    market    life    chemotherapy    reduce    gamma    grade    unprecedented    clinical    safety    allogeneic    treatment    limited    cancers    segments    weeks    delta    clinicians    solution    regardless   

Project "OmnImmune" data sheet

The following table provides information about the project.

Coordinator
TC BIOPHARM LIMITED 

Organization address
address: MAXIM 1 PARKLANDS WAY 2 HOLYTOWN MOTHERWELL LANARKSHIRE
city: HOLYTOWN
postcode: ML14WQ
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.omnimmune-h2020.com
 Total cost 3˙957˙000 €
 EC max contribution 3˙957˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TC BIOPHARM LIMITED UK (HOLYTOWN) coordinator 3˙957˙000.00

Map

 Project objective

Europe is experiencing an unprecedented cancer epidemic, driven by our ageing population. Traditional cancer treatments such as surgery, chemotherapy and radiation therapy have demonstrated very limited efficacy for patients with late-stage disease and often cause considerable side effects. Cell therapies are the next breakthrough in oncology, but autologous cells must be harvested from each patient, expanded for several weeks in vitro and re-administered to the same patient while hospitalized. TCB, a Scottish SME, brings the first allogeneic gamma delta T cell therapy (OmnImmune) where T cells harvested from healthy donors are used to treat multiple recipients. OmnImmune represents a truly disruptive, step-changing approach to the treatment of a wide variety of cancers. It has the potential to be manufactured for large market segments at a lower cost than competitors and provide valuable increases to the quality of life of life. OmnImmune will provide next generation cancer treatment at 20% of the cost of any other cell therapy, saving €24Bn per year for 60,000 patients treated. OmnImmune’s unique characteristics make it a truly disruptive treatment solution for patients and clinicians: Multifunctional treatment solution: available to all cancer patients, regardless of their disease grade or immune status Predicted high safety profile: minimal side-effects based on clinical data from trials of autologous GDT cells (to be confirmed in dose-escalation clinical trial) Ease of use and lower cost: frozen dose-ready units available for immediate patient administration. The SME Instrument funding will accelerate the development of the OmnImmune therapy and reduce its time to market from 10 years to 6 years. This will allow OmnImmune to reach the market by 2024.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OMNIMMUNE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OMNIMMUNE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

Read More